Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer

Wen-Zhao Zhong and colleagues’ trial1 shows that adjuvant gefitinib led to 28· 7 months (95% CI 24· 9–32· 5) of disease-free survival, compared with 18· 0 months (13· 6–22· 3) with vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-smallcell lung cancer (NSCLC)(hazard ratio [HR] 0· 60, 95% CI 0· 42–0· 87; p= 0· 0054). However, several caveats should be kept in mind. First, diseasefree survival was much shorter than in other trials of adjuvant vinorelbine plus cisplatin in resected NSCLC. 2 Second, only 3% of patients included had undergone pneumonectomies, by contrast with an average of 25% in other studies. 2 Third, the median number of chemotherapy cycles received was four and dose reductions were not clearly defined; in previous studies, only about 60% of patients complete the planned four cycles. 2 Fourth, the authors do not report the pattern of …